Question 1

Who are the top researchers at PersonGen (China)?

Accepted Answer

Ranked on the quality score, Fengtao You lead among researchers whose main affiliation is PersonGen (China).

Question 2

What are the most cited papers from PersonGen (China)?

Accepted Answer

The most cited paper from PersonGen (China) is "Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia." (Xiaowen Tang, Lin Yang, Zheng Li et al., 2018), with 412 citations. Next come "Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells" (153) and "A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia." (130).

Question 3

Which research topics does PersonGen (China) publish most on?

Accepted Answer

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, Monoclonal and Polyclonal Antibodies Research and Glioma Diagnosis and Treatment.

Question 4

Which fields of science does PersonGen (China) work in?

Accepted Answer

In all years, 57% of research at PersonGen (China) is in Health Sciences, 32% in Life Sciences. Its largest fields are Medicine (57%), Biochemistry, Genetics and Molecular Biology (16%), Immunology and Microbiology (15%). It does 1.8× the world's share of Health Sciences.

Question 5

Is PersonGen (China)'s research output growing?

Accepted Answer

Output in 2022-2025 was 2% higher than in 2018-2021.